Advertisement

The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial

  • Mojca Lunder
    Correspondence
    Corresponding author at: Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Korytkova 2, SI-1000 Ljubljana, Slovenia. Tel.: +386 15437353; fax: +386 15437331.
    Affiliations
    Department of Vascular Disease, University of Ljubljana Medical Centre, Zaloška 7, 1000 Ljubljana, Slovenia

    Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia
    Search for articles by this author
  • Miodrag Janić
    Affiliations
    Department of Vascular Disease, University of Ljubljana Medical Centre, Zaloška 7, 1000 Ljubljana, Slovenia
    Search for articles by this author
  • Borut Jug
    Affiliations
    Department of Vascular Disease, University of Ljubljana Medical Centre, Zaloška 7, 1000 Ljubljana, Slovenia
    Search for articles by this author
  • Mišo Šabovič
    Affiliations
    Department of Vascular Disease, University of Ljubljana Medical Centre, Zaloška 7, 1000 Ljubljana, Slovenia
    Search for articles by this author
Published:December 14, 2011DOI:https://doi.org/10.1016/j.ejim.2011.11.011

      Abstract

      Background

      Ageing progressively diminishes arterial functions, even in the absence of traditional risk factors. Our aim was to explore whether age-related arterial changes in middle-aged males could be reversed using short-term, low-dose fluvastatin/valsartan combination intervention.

      Methods

      Forty apparently healthy, middle-aged males (43.3±5.8 years) were recruited in a double-blind, randomised intervention. Individuals received either 10 mg fluvastatin/20 mg valsartan daily or placebo over 30 days. The brachial artery flow mediated dilation (FMD), pulse wave velocity (PWV) and common carotid artery β-stiffness were assessed at baseline and after 30 days, and again 5–10 months after therapy discontinuation.

      Results

      Arterial function variables significantly improved after 30 days of intervention; FMD improved by 167.7% (P<0.001), PWV by 10.9% (P<0.05) and β-stiffness by 18.8% (P<0.01), whereas no changes were obtained in the placebo group. The favourable outcomes in the intervention group were accompanied by a significant decrease of high sensitivity-C reactive protein levels (1.8-fold; P<0.05). In contrast, lipids and blood pressure remained unchanged. Surprisingly, the beneficial arterial effects were still present to a substantial degree 7 months after completing intervention (remaining % of initial improvement: FMD 82.1%, PWV 69.5% and β-stiffness 68.5%), but declined substantially after 10 months.

      Conclusion

      Our results indicate that age-related arterial changes, at least in middle-aged males, can be reversed. Short-term treatment with a low-dose fluvastatin/valsartan combination resulted in a large and long lasting improvement of arterial function.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nilsson P.M.
        • Boutouyrie P.
        • Laurent S.
        Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention.
        Hypertension. 2009; 54: 3-10
        • Pepe S.
        • Lakatta E.G.
        Aging hearts and vessels: masters of adaptation and survival.
        Cardiovasc Res. 2005; 66: 190-193
        • Carerj S.
        • Nipote C.
        • Zimbalatti C.
        • Zito C.
        • Sutera Sardo L.
        • Dattilo G.
        • et al.
        Normal vascular aging evaluated by a new tool: e-tracking.
        Eur J Echocardiogr. 2006; ([suppl: S]): 49
        • Lind L.
        Impact of ageing on the measurement of endothelium-dependent vasodilation.
        Pharmacol Rep. 2006; 58: 41-46
        • Hadi H.A.
        • Carr C.S.
        • Al Suwaidi J.
        Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.
        Vasc Health Risk Manag. 2005; 1: 183-198
        • Wykretowicz A.
        • Gerstenberger P.
        • Guzik P.
        • Milewska A.
        • Krauze T.
        • Adamska K.
        • et al.
        Arterial stiffness in relation to subclinical atherosclerosis.
        Eur J Clin Invest. 2009; 39: 11-16
        • Laurent S.
        • Cockcroft J.
        • Van Bortel L.
        • Boutouyrie P.
        • Giannattasio C.
        • Hayoz D.
        • et al.
        Expert consensus document on arterial stiffness: methodological issues and clinical applications.
        Eur Heart J. 2006; 27: 2588-2605
        • Tomiyama H.
        • Yamashina A.
        Non-invasive vascular function tests: their pathophysiological background and clinical application.
        Circ J. 2010; 74: 24-33
        • Blum A.
        • Shamburek R.
        The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis.
        Atherosclerosis. 2009; 203: 325-330
        • Jankowski P.
        • Safar M.E.
        • Benetos A.
        Pleiotropic effects of drugs inhibiting the renin–angiotensin–aldosterone system.
        Curr Pharm Des. 2009; 15: 571-584
        • Sugiyama M.
        • Ohashi M.
        • Takase H.
        • Sato K.
        • Ueda R.
        • Dohi Y.
        Effects of atorvastatin on inflammation and oxidative stress.
        Heart Vessels. 2005; 20: 133-136
        • Castilla Guerra L.
        • del Carmen Fernandez Moreno M.
        • Lopez Chozas J.M.
        • Jimenez Hernandez M.D.
        Statins in stroke prevention: what an internist should know.
        Eur J Intern Med. 2008; 19: 8-14
        • Hussein O.
        • Shneider J.
        • Rosenblat M.
        • Aviram M.
        Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
        J Cardiovasc Pharmacol. 2002; 40: 28-34
        • Horiuchi M.
        • Cui T.X.
        • Li Z.
        • Li J.M.
        • Nakagami H.
        • Iwai M.
        Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
        Circulation. 2003; 107: 106-112
        • Liu L.
        • Zhao S.P.
        • Zhou H.N.
        • Li Q.Z.
        • Li J.X.
        Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
        J Cardiovasc Pharmacol. 2007; 50: 50-55
        • Lunder M.
        • Janic M.
        • Habjan S.
        • Sabovic M.
        Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males a pilot study.
        Atherosclerosis. 2011; 215: 446-451
        • Lunder M.
        • Janic M.
        • Sabovic M.
        Reduction of age-associated arterial wall changes by low-dose valsartan.
        Eur J Cardiovasc Prev Rehabil. 2011; https://doi.org/10.1177/1741826711423104
        • Corretti M.C.
        • Anderson T.J.
        • Benjamin E.J.
        • Celermajer D.
        • Charbonneau F.
        • Creager M.A.
        • et al.
        Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.
        J Am Coll Cardiol. 2002; 39: 257-265
        • Celermajer D.S.
        • Sorensen K.E.
        • Gooch V.M.
        • Spiegelhalter D.J.
        • Miller O.I.
        • Sullivan I.D.
        • et al.
        Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
        Lancet. 1992; 340: 1111-1115
        • Koh K.K.
        • Han S.H.
        • Oh P.C.
        • Shin E.K.
        • Quon M.J.
        Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.
        Atherosclerosis. 2010; 209: 307-313
        • Yoshikawa M.
        • Nakamura K.
        • Nagase S.
        • Sakuragi S.
        • Kusano K.F.
        • Matsubara H.
        • et al.
        Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis.
        J Cardiovasc Pharmacol. 2009; 53: 179-186
        • van Haelst P.L.
        • van Doormaal J.J.
        • May J.F.
        • Gans R.O.
        • Crijns H.J.
        • Tervaert J.W.
        Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein.
        Eur J Intern Med. 2001; 12: 503-509
        • Skogastierna C.
        • Luksha L.
        • Kublickiene K.
        • Eliasson E.
        • Rane A.
        • Ekstrom L.
        Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide.
        Heart Vessels. 2011; https://doi.org/10.1007/s00380-010-0097-x
        • Ridker P.M.
        • MacFadyen J.G.
        • Fonseca F.A.
        • Genest J.
        • Gotto A.M.
        • Kastelein J.J.
        • et al.
        Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
        Circ Cardiovasc Qual Outcomes. 2009; 2: 616-623